Setting a Research Agenda for Progressive MS: The International Collaborative on Progressive MS
Robert J. Fox, Alan Thompson, David Baker, Peer Baneke, Doug Brown, Paul Browne, Dhia Chandraratna, Olga Ciccarelli, Timothy Coetzee, Giancarlo Comi, Anthony Feinstein, Raj Kapoor, Karen Lee, Marco Salvetti, Kersten Sharrock, Ahmed Toosy, Paola Zaratin and Kim Zuidwijk
Multiple Sclerosis Journal
Despite significant progress in the development of therapies for relapsing MS, progressive MS remains comparatively disappointing. Our objective, in this paper, is to review the current challenges in developing therapies for progressive MS and identify key priority areas for research. A collaborative was convened by volunteer and staff leaders from several MS societies with the mission to expedite the development of effective disease-modifying and symptom management therapies for progressive forms of multiple sclerosis. Through a series of scientific and strategic planning meetings, the collaborative identified and developed new perspectives on five key priority areas for research: experimental models, identification and validation of targets and repurposing opportunities, proof-of-concept clinical trial strategies, clinical outcome measures, and symptom management and rehabilitation. Our conclusions, tackling the impediments in developing therapies for progressive MS will require an integrated, multi-disciplinary approach to enable effective translation of research into therapies for progressive MS. Engagement of the MS research community through an international effort is needed to address and fund these research priorities with the ultimate goal of expediting the development of disease-modifying and symptom-relief treatments for progressive MS.